fenbufen

Fenbufen is a nonsteroidal anti-inflammatory drug (NSAID) of the propionic acid derivative class. It was primarily used to treat inflammation and pain associated with osteoarthritis, ankylosing spondylitis, tendinitis, rheumatoid arthritis, and musculoskeletal injuries such as backaches, sprains, and fractures[1][2][7]. Fenbufen acts by inhibiting cyclooxygenase enzymes (COX1 and COX2), thereby preventing the synthesis of prostaglandins that mediate inflammation and pain[2][3][5]. Its anti-inflammatory activity is mainly attributed to its active metabolite, 4-biphenylacetic acid[5]. Fenbufen was originally introduced by American Cyanamid under the trade name Lederfen in the 1980s but was withdrawn from markets in developed countries due to liver toxicity concerns; however, it has remained available in some regions such as Taiwan and Thailand under various brand names[7].

Brand names

LederfenCinopalCepalCybufenReugast

Other names

gamma-oxo(1,1'-biphenyl)-4-butanoic acid3-(4-Biphenylylcarbonyl)propionic acid3-(4-Phenylbenzoyl)propionic acid4-(4-Biphenylyl)-4-oxobutyric acidfenbufénfenbufènefenbufenum